Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jul 8, 2026

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

Evaluating new treatment options for MDS.

Guillermo Garcia-Manero1, Allen S Yang, Madan Jagasia

  • 1The University of Texas, M.D Anderson Cancer Center in Houston, USA.

Clinical Advances in Hematology & Oncology : H&O
|January 17, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Need for aligning the definition and reporting of cytokine release syndrome (CRS) in immuno-oncology clinical trials.

Cytotherapy·2022
Same author

Impact of Chromosomal Rearrangement upon DNA Methylation Patterns in Leukemia.

Open medicine (Warsaw, Poland)·2017
Same author

Phase I Study of Fenretinide Delivered Intravenously in Patients with Relapsed or Refractory Hematologic Malignancies: A California Cancer Consortium Trial.

Clinical cancer research : an official journal of the American Association for Cancer Research·2017
Same author

Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical study.

Leukemia & lymphoma·2016
Same author

Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis.

Cancer·2016
Same author

Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapy.

American journal of hematology·2016

Myelodysplastic syndromes (MDS) are blood disorders with new treatments offering improved survival. Recent advances include growth factors, iron chelation, and novel agents like lenalidomide, azacitidine, and decitabine.

Area of Science:

  • Hematology
  • Oncology

Background:

  • Myelodysplastic syndromes (MDS) are clonal hematopoietic stem cell disorders.
  • Characterized by ineffective hematopoiesis and peripheral cytopenias affecting granulocyte, erythrocyte, and megakaryocyte lineages.
  • Associated with specific chromosomal abnormalities (e.g., 7q, 5q, 20q).

Purpose of the Study:

  • To review the evolving treatment landscape for Myelodysplastic syndromes (MDS).
  • To highlight recent advancements in supportive care and novel therapeutic agents.
  • To discuss the potential impact of these changes on patient survival and quality of life.

Main Methods:

  • Review of current literature and recent clinical trial data for MDS treatments.
  • Analysis of supportive care strategies including growth factors and iron chelation.

More Related Videos

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation
12:05

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation

Published on: November 3, 2018

A Murine Ommaya Xenograft Model to Study Direct-Targeted Therapy of Leptomeningeal Disease
07:17

A Murine Ommaya Xenograft Model to Study Direct-Targeted Therapy of Leptomeningeal Disease

Published on: January 29, 2021

Related Experiment Videos

Last Updated: Jul 8, 2026

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation
12:05

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation

Published on: November 3, 2018

A Murine Ommaya Xenograft Model to Study Direct-Targeted Therapy of Leptomeningeal Disease
07:17

A Murine Ommaya Xenograft Model to Study Direct-Targeted Therapy of Leptomeningeal Disease

Published on: January 29, 2021

  • Evaluation of newly approved agents targeting MDS pathophysiology: lenalidomide, azacitidine, and decitabine.

    • Main Results:

    • Supportive care, enhanced by growth factors and iron chelation, can prolong survival in MDS patients.
    • Lenalidomide, azacitidine, and decitabine demonstrate significant activity and potential survival benefits in specific MDS subgroups.
    • These novel agents target underlying molecular pathways crucial to MDS development.

    Conclusions:

    • The treatment paradigm for Myelodysplastic syndromes is rapidly evolving with new therapeutic options.
    • Novel agents and refined supportive care strategies offer improved outcomes for MDS patients.
    • Future research will focus on combination therapies to further optimize MDS treatment.